1989.-The effect of angiotensin II (ANG II) and arginine vasopressin (AVP) on prostacyclin production by vascular smooth muscle cells (VSMC) has been examined. Cultured rat aortic VSMC were studied during either static incubation in multiwell plates or during dynamic incubation in superfusion columns. Prostacyclin synthesis was assessed by radioimmunoassaying one of its stable metabolites, 6-keto-prostaglandin F1, (6-keto-PGF1,). Both ANG II and AVP stimulated the biosynthesis of prostacyclin in a concentration-dependent manner (10-l' to 10m5 M). ANG II (EDso = 3 nM) displayed a higher potency than AVP (EDso = 10 nM). ANG II was 4.4 times more potent than AVP at IO-' M. The effect of both peptides was inhibited selectively by antagonists. In the case of AVP (lo-' M), a pure V1 antagonist (dEt,AVP) and the Vz agonist dDAVP, both at 10m6 M, completely blocked the production of prostacyclin induced by AVP, whereas a mixed VI-V2 antagonist [d(CH&-D-Leu-VAVP] at 10e6 M displaced the concentration-response curve by approximately two orders of magnitude to the right. Superfusion with a calciumfree medium containing ethylene glycol-bis(P-aminoethyl ether)-N,N,N',N'-tetraacetic acid inhibited 89 t 3% of the ANG II-and 70 t 8% of the AVP-induced prostacyclin production, whereas nifedipine (10e6 M) had no effect. A potentiating effect was observed when the stimulation with either ANG II or AVP was repeated two or three times. An even more marked potentiation resulted when the stimulation by ANG II (lo-" M) followed stimulation by AVP (lo-' M). This potentiation was still observed in the presence of AVP antagonists or when the concentration of AVP was reduced to 10ql' M, circumstances in which AVP had no or a minimal direct stimulatory effect. We conclude that some link must be generated by the interaction of ANG II and AVP through their respective receptors and the ensuing transmembrane signaling systems on VSMC. In addition it appears that the nature of the AVP receptor linked to prostacyclin generation cannot be simply ascribed to a V1 or V, subtype.
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nifedipine; indomethacin; calcium; aorta; rat PROSTAGLANDIN (PG) biosynthesis is known to occur in vascular smooth muscle cells (VSMC) . Prostacyclin (PGIJ is the major prostanoid in incubates of freshly prepared aortic (24) or cultured mesenteric (10) smooth muscle cells. Prostacyclin is also one of the most potent vascular relaxing agents among the prostanoids synthesized in the vascular wall (7, 17). Prostaglandins attenuate a number of biological responses of target cells for various circulating hormones, such as arginine vasopressin (AVP) and angiotensin II (ANG II), in the kidney (6) or in the vasculature (19, 21) . It is of interest, therefore, that these vasoactive peptides in turn stimulate prostaglandin biosynthesis in various target cells. There is relatively little knowledge, however, concerning the interaction of ANG II and AVP with VSMC prostacyclin synthesis and with other vasoactive agents.
In the present study we have chosen the rat aortic smooth muscle cells as target cells that can be cultured without significant contamination by endothelial cells or fibroblasts. These smooth muscle cells retain ANG II and AVP receptors in culture (1, 9, 22) and respond i n a concentration-dependent manner by a rapid rise of CYtosolic free calcium. This occurs in part through mobilization of calcium from an intracellular pool and through activation of receptor -operated calcium channels (I, 20) .
A parallel production of PG12 was also observed i .n these cells (2, 9, 23) .
In this study, two different approaches have been utilized to examine these relationships including 1) a dynamic technique using cells superfused in specially designed Teflon columns allowing repetitive stimulation with agonists and/or antagonists that minimizes enzymatic destruction of the peptide hormones and prevents the accumulation of arachidonic acid metabolites that could (directly or indirectly) affect the sustained response of the cells; and 2) a static technique using multiwell culture plates that permits multiple parallel assays of various agents on samples of the same cell population, whereas circumventing problems of tachyphylaxis and agonist interactions. Preparation and culture of rat aortic smooth muscle cells. Rat aortic smooth muscle cells were prepared by enzymatic dispersion under sterile conditions by a modification of the method described by Gunther et al. (1, 7) . Six female Wistar rats (6-8 wk old, weighing 180-200 g) were killed b y cervical dislocation under ether anesthesia. Their thoracic aortas were removed and placed on ice in DMEM [pH 7.4; 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer, 2 mM L-glutamine, 100 U/ml penicillin, and 100 pg/ml streptomycin]. The aortas were cleaned of fat and connective tissue, and the adventitia were stripped using a watchmaker forceps under a binocular microscope. The tissue was then minced and transferred into a X-ml plastic tube containing 6 ml of enzyme dissociation mixture (DMEM with 2 mg/ml of collagenase type I, 0.5 mg/ ml of elastase type IV, and 1 mg/ml of soybean trypsin inhibitor). The suspension was incubated for 2 h at 37" C under constant agitation. The supernatant containing the dispersed smooth muscle cells was collected, and the cells were washed twice with DMEM supplemented with 10% FCS and resuspended in DMEM without FCS. This dispersed cell suspension was pipetted into two go-mm Petri dishes and cultured at 37°C in a humidified atmosphere composed of 95% air-5% COz. After 2 h, the medium was supplemented with 10% FCS. Cells were adherent after 24 h and were washed once with DMEM. Confluent monolayers with a cell density of lo7 cells/ Petri dish were usually obtained after 7 days. Confluent cultures were passaged by incubating them with 2 ml of 0.25% trypsin in low-calcium medium for 10 min at 37OC. After dilution with 38 ml of DMEM containing 10% FCS and 20 mM sodium bicarbonate instead of HEPES buffer, the suspension was split into two 90-mm Petri dishes. Subsequent passages were performed at 48-to 72-h intervals after confluence of the cells. After four passages, the cells still contained a predominant VSMCspecific actin. With increased passages the expected phenotypic modulation characterized by a predominance of ,& over cu-actin was observed, as assessed by two-dimensional gel electrophoresis (8, 14) .
MATERIALS AND METHODS

Materials
Preparation of the columns. Specially designed Teflon columns (18, 27) were stored in HCl (1 N). After rinsing with distilled water, a 30-pm mesh nylon gauze was inserted into each column, then 0.2 g of Bio-Gel polyacrylamide beads (P2, 200-400 mesh; Bio-Rad), were swollen overnight in sterile 0.9% NaCl and layered on the nylon gauze to provide an inert supporting matrix for the cells. The Bio-Gel was then equilibrated for 30 min with the superfusion buffer (Krebs-Ringer-glucosebicarbonate, pH 7.4, with 0.2% BSA (27) .
Superfusion of isolated smooth muscle cells. Between the third and the fifth passage the cells were harvested after a 15-to 20-min trypsinization. The detached dispersed cells were resuspended in DMEM containing 10% FCS and centrifuged at 1,200 rpm for 5 min. The cell number was counted and 3-6 x lo6 cells in up to 1.2 ml of DMEM were loaded on the Bio-Gel layer. While the cells were settling, the columns were filled with the superfusion medium, closed free of air, placed in a water bath at 37"C, and superfused at a flow rate of 250 pl/ min. The media without or with the various agents to be tested were kept in a water bath at 37°C and gassed with a mixture of 95% 02-5% COz. Two or four columns were perfused in parallel using a peristaltic multichannel pump (model IP-8, Ismatec, Zurich, Switzerland) for periods up to 3 h. The viability of the cells was examined by their ability to respond to stimuli at the end of the superfusion and to exclude trypan blue at the end of each experiment. No preparation had X0% of its cells that were considered nonviable by this technique.
Experimental design. The columns were superfused for a period of 60 min with the buffer to insure stable basal values of prostacyclin production. Thereafter, 5-min fractions were collected. After 15 min the stimuli were applied for periods of 10 min separated by a 30-min interval to allow a return to basal values. Fractions were stored at -20°C until assayed within a week. When the effects of indomethacin and nifedipine on prostacyclin release were tested, these compounds were added to all of the superfusion media at a final concentration of 3 x 10e6 M and 10B6 M, respectively. The stock solution and buffer reservoir containing nifedipine were protected from light by aluminum foil. Binding of the peptides and other compounds to the vials and the plastic tubing was minimized by adding 0.2% BSA to the perfusion buffer.
Static incubation. After three to five passages the cells were harvested, and 0.5 ml of the cell suspension was added to each of the 24 holes of a multiwell culture plate and an additional 0.5 ml of DMEM with FCS was added. When the cells were confluent, the supernatant was removed and washed with 1 ml of fresh DMEM without FCS, then 1 ml of incubation medium. The cells were then preincubated during 30 min at 37OC. The supernatant was removed and replaced by 1 ml of medium containing the various agents to be tested. The cells were subsequently incubated for 1 h at 37°C in a humidified atmosphere of 95% air-5% COa. At the end of the incubation period, the medium was gently aspirated and centrifuged at 3,000 rpm for 5 min, and the supernatant was frozen at -20°C until its assay for 6-keto-PGF,,. The remaining cells were washed twice with 1 ml tris(hydroxymethyl)aminomethane (Tris) . HCl buffer, pH 7.4, then removed by scraping and resuspended for protein determination according to Lowry et al. (16) .
Assay of 6-keto-PGF,,. The stable metabolite of prostacyclin was measured directly by radioimmunoassay on a 50-~1 aliquot from each fraction, using tritiated 6-keto-PGF1, and a specific rabbit antiserum. The limit of detection in the assay tube is 1 pg; this corresponded to 24 pg/fraction eluted from the columns and 20 pg/well in the static incubation. The cross-reactivity of the rabbit antiserum against 6-keto-PGF1, was 14% with PGF1,, 2% with PGE1, 1.7% with PGFzLY, and <l% with the other major arachidonic acid metabolites. All fractions were assayed in duplicate. Intra-and interassay coeficients of variation were 4% (mean 969 t 8.6 pg/ml; n = 20) and 8.3% (mean 835 t 11 pg/ml; n = 40), respectively.
In initial experiments PGEz and PGFZ, were also measured by radioimmunoassay as previously described (27). As expected, values much lower than for 6-keto-PGF,, were found. Statistics.
The prostacyclin response to stimulation was calculated as the total increment above base line (area under peak minus average base line of a corre- 
RESULTS
Effect of AVP and ANG II. Superfused rat aortic smooth muscle cells responded rapidly within 5 min of exposure to either AVP (IO-' M) or ANG II (low8 M) with an increase in 6-keto-PGF1, production that ceased within 5 min after removal of the stimulus (Fig. 1) . The effluent was collected at l-min intervals during the first 5 min of stimulation with AVP (n = 10) and ANG II (n = 8). A significant rise was observed between the 2nd and 4th min after the onset of the stimulation with each peptide. These sharp peaks were clearly distinct from the basal production, which rarely rose over 100 pg 6-keto-PGF1, l lo6 cells-' l 5 min-' and was generally below 50 pg* lo6 cells-l -5 min-' or the lower limit of detection (24 pg). Indomethacin (3 x low6 M), when added to the perfusion buffer of five columns in four separate experiments, suppressed entirely the release of 6-keto-PGF,, induced by either ANG II or AVP at IO-' M (95 t 69 and 98.6 t 65, respectively, compared with a base line of 100 t 72 pg/106 cells). A concentration-dependent increase in the production of 6-keto-PGF1, was observed after exposure of the VSMC to increasing concentrations of ANG II or AVP during static incubation (Figs. 2 and  3 ). An apparent EDs0 of -3 nM was computed for ANG II. The ED,, could not be accurately computed for AVP when the concentration-response curve did not reach a distinct plateau (Fig. 3 ). An estimated value of 10 nM (Fig. 4) was derived. More marked than this difference in sensitivity was the difference in efficacy between ANG II and AVP with the former generally being 2-10 times more effective than the latter. completely prevented the AVP-induced production of prostacyclin at all concentrations in static incubation (Fig. 4) .
The selectivity of this blockade by antagonists of AVP and of ANG II effects on the 6-keto-PGF1, release was demonstrated in superfusion studies by the fact that dEt,AVP ( 10m6 M) did not inhibit the ANG II ( 10v8 M)-induced 6-keto-PGF1, release (1,345 t 99 compared with 1,644 t 66 pg/106 cells) and that [ Sar',Ala']ANG II ( 10m6 M) did not inhibit the AVP (low8 M)-induced 6-keto-PGF1, release (829 t 307 compared with 483 t 92 pg/ lo6 cells). None of these antagonists stimulated prostacyclin production when superfused alone; dDAVP displayed a weak stimulating effect when perfused alone. Potentiation between ANG II and AVP. The sequence of stimulation of the cells by these agents determined the amplitude of the response to either peptide. As seen in Fig. 1, prior Effect of various antagonists on ANG II and AVPinduced release of 6-keto-PGF,,.
In static incubations, [Sar',Ala']ANG II ( 10m6 M) shifted the concentrationresponse curve to the right by approximately three orders of magnit<ude (Fig. 2) ANG II (lo-' M). This was apparent when the concentration of AVP was lowered to 10-l' M, at which AVP had minimal if any direct stimulatory effect (Fig. 5 ).
Repetitive stimulation with ANG II (10B8 M) after superfusion with AVP resulted in a lesser release of 6-keto-PGF1,. We, therefore, sought to demonstrate whether repeated stimulation with the same agent would affect the response. In Fig. 6 , the elution profiles of four columns, run in parallel, are depicted. In Fig. 6 (top), three successive stimulations 40 min apart with either AVP (left) or ANG II (right) at 10m7 M resulted in a progressive increase in the production of 6-keto-PGF1,. Figure 6 (bottom) demonstrates that AVP (low7 M) markedly potentiated the production of 6-keto-PGF1, by subsequent ANG II ( low7 M) stimulation. This potentiation appeared to be maintained over an hour because a second stimulation by ANG II, although resulting in a somewhat reduced peak compared with the first, was still greater than any when the ANG II was not preceded by AVP (Figs. 5 and 6 ). To a lesser extent, the 6-keto-PGF1, response to AVP was also greater when it was preceded by ANG II rather than applied as a first stimulus. We therefore examined the potentiating effect of AVP on ANG II-induced production of 6-keto-PGF1,.
The effect of the order of stimulation by ANG II and AVP on incremental 6-keto-PGF1, release is shown in Fig. 7 . The marked potentiation of the ANG II action induced by AVP is evident, although there was a much less pronounced effect of ANG II on the subsequent AVP stimulation. This is more obvious when the ratio of the increase of 6-keto-PGF1, release to sequential stimulation is calculated. When ANG II (IO-' M) was applied sequentially at 40-min intervals, the ratio of the second peak over the first was 2.41 t 0.4 (n = 8). When AVP (lo-' M) was applied twice under the same conditions the corresponding ratio amounted to 1.68 t 0.26 (n = 4). By contrast the ratio of the 6-keto-PGF,, release induced by ANG II over that induced by AVP was 2.26 +-0.27 (n = 8), when ANG II was the first stimulus, whereas when ANG II was applied as second stimulus after prior exposure to AVP, this ratio amounted to 11 t 1.2 (n = 9). When the period of stimulation of the cells by AVP (low8 M) was prolonged from 10 to 30 and 50 min [reducing correspondingly the period before the subsequent stimulation by ANG II (10m8 M) from 40 to 20 min and to an immediate stimulation], the production of 6-keto-PGF1, increased was to 1,981, 2,281, and 2,036 pg/106 cells, respectively, compared with 1,096 pg/106 cells when, in the same experiment, the cells had been exposed first to ANG II.
Several experiments were performed to determine if specific receptor blockade or occupancy would alter the potentiating effect of AVP or ANG II-stimulated prostacyclin production. Forty minutes before stimulation by ANG II (lo-' M), the cells were exposed for 10 min to AVP (lo-' M) combined with an antagonist at 10s6 M or to the antagonist alone. When the antagonist was perfused in combination with AVP, it was begun 5 min before and continued for 5 min after AVP for a total of 20 min. Both the pure anti-V1 antagonist dEt,AVP and the mixed V& (but predominantly V,) antagonist d(CH&-D-Leu-VAVP completely inhibited the AVP-induced 6-keto-PGF1, release from 1,355.g t 624 to 26.0 t 12.5 and 172 t 28 pg/106 cells, respectively, and a base line of 19 t 8.4 pg/106 cells. Yet despite this blockade, a potentiation (1.85-fold) of the subsequent ANG II-induced prostacyclin synthesis was still elicited from 873 t 388 to 1,612 t 98 (n = 4) pg/106 cells. None of these antagonists stimulated 6-keto-PGF1, during the first or last 5 min period during which they were perfused alone. Similarly, if the cells were exposed during 10 min to dEt,AVP (10m6 M) alone, no significant increase of 6-keto-PGF,, release above base line occurred (48.3 vs. 51.3 pg/106 cells), yet the production in response to a subsequent stimulation by ANG II (10s8 M) was potentiated twofold from 919 t 228 to 1,798 t 45 pg/106 cells. When, in the same experiments, this scheme was repeated with dDAVP ( 10B6 M), this V2 receptor agonist stimulated weakly the production of 6-keto-PGF,, 3.8 t 1.4 times the basal production and potentiated the subsequent response to ANG II (10B8 M) by a factor of 1.56. In eight separate experiments, comprising altogether 10 columns, [ Sar1,Ala8]Ang II ( 10B6 M) when perfused prior and during ANG II (10m8 M) blocked the production of 6-keto-PGF1, despite prior stimulation by AVP (lo-' M) from lJ95.8 to 204.8 pg/106 cells compared with a basal production of 27.8 t 10 pg/106 cells.
Effects of extracellular Ca2+ and of calcium channel blockade on ANG II and AVP-induced prostacyclin production by superfused aortic smooth muscle cells. Removal of calcium from the superfusion medium by using a calcium-free medium supplemented with ethylene glycol-(P-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA; 10m3 M) inhibited by 89 t 3 and 70 t 8% the stimulation of 6-keto-PGF1, release induced by ANG II and AVP, respectively. The voltage-gated calcium channel blocker nifedipine (10s6 M) added to the superfusion medium had no effect whatsoever on either the ANG IIor the AVP-induced stimulation of prostacyclin production (1,160 t 329 and 813 t 372 pg/106 cells, respectively). The role of calcium in the potentiating effect of AVP was also examined. The cells were first perfused with AVP (low8 M) in the absence of calcium and the presence of EGTA and then stimulated by ANG II (low8 M) after the calcium concentration had been restored. This protocol resulted in the persistence of the potentiating effect; the production of 6-keto-PGF1, under ANG II was 2,159 t 567 pg/106 cells after AVP stimulation in low-calcium medium compared with 2,138 t 1,862 pg/106 cells when calcium was present during stimulation by AVP, whereas 1,224 t 276 pg/106 cells were produced when the cells were first stimulated by ANG II (n = 4). Similarly, prior exposure of the cells to AVP (lo-8 M) in the presence of nifedipine (low6 M) did not alter the potentiating effect. AVP stimulation in the presence (639 t 63 pg/lO" cells) or the absence of nifedipine (541 t 13 pg/106 cells) was followed by a similar response to ANG II (1,711 t 5 compared with 1,614 t 102 pg/106 cells, respectively).
DISCUSSION
Two techniques have been employed in the present study to examine the stimulation of prostacyclin biosynthesis in rat aortic smooth muscle cells. The same superfusion technique (18) previously applied to freshly isolated rat renal tubular cells (26, (27) (28) (29) has permitted us to show a significant interaction of AVP and ANG II on the production of prostacyclin in smooth muscle cells. The present study demonstrates that cultured rat aortic smooth muscle cells respond, as do mesenteric artery smooth muscle cells (1 I), within minutes after exposure to ANG II and AVP by the production of prostacyclin and this ceases immediately on removal of the stimulus.
In contrast to rat tubular cells, the major prostanoid synthesized in rat aortic smooth muscle cells, similar to rat mesenteric smooth muscle cells (10, 24), was prostacyclin with PGE2 and PGFzcy being released in much lower quantities. Contrary to observations in rat renal tubular cells (27) , no tachyphylaxis was observed in rat aortic smooth muscle cells repetitively exposed at 40-min intervals to ANG II or AVP. Rather, a progressive and distinct increase of 6-keto-PGF1, responsiveness was observed. Furthermore, an unexpected and marked potentiation of the response to ANG II was observed after prior exposure to AVP. This potentiation occurred even when AVP was superfused at a concentration that had marginal or no stimulatory effect on prostacyclin biosynthesis. This potentiation was also observed when the direct effect of AVP was entirely inhibited by the selec- Because a very low dose of AVP (lOwl' M) but not ANG II itself at IO-' M provoked a marked potentiating effect, a protective effect by saturation of degrading enzymes appears excluded, particularly in the superfusion system. This potentiating effect was not prevented by V1 or V, antagonists that block the AVP-induced release of prostacyclin. Therefore, this potentiating effect might result from some link generated by the interaction of ANG II and AVP through thei ensuing transmembrane r Si respective receptors and the .gnaling systems. It is also conceivable that blockade of the AVP action by the antagonists was not complete, particularly in terms of second messenger generated: for example, in the presence of the antagonist an amount of agonist would be left active corresponding to 10wl' M or less, insufficient for raising prostacyclin production but able to generate a sufficient intracellular signal to prepare the cells for potentiation of the response to a subsequent stimulus. This potentiation lasted for at least 90 min and is compatible with the hypothesis that a postreceptor event of prolonged duration is involved. Because each of the agonists appears to act via the phosphatidylinositol transduction system, protein kinase C activation would be a likely candidate.
The receptors for ANG II and AVP are specific for each of their respective peptides bet ause the stimulatory effects could be blocked by selec tive antagon ists without cross-effect. This was studied in greater detail using static incubation techniques that permitted establishment of concentration-response curves using the same preparation of cells and without the interaction of repetitive stimuli. As with the superfusion technique, the rat aortic smooth muscle cells were more sensitive to ANG II than to AVP in terms of prostacyclin biosynth .esis with an approximate EDso that was 10 times lower for ANG II than for AVP. This is in keeping with the data of Penit et al. (ZZ), who calculated a maximal capacity of ANG II receptors twice that of AVP receptors and a & for AVP that was 10 times higher than for ANG II. If the existence of spare receptors is taken in account, one should assume that for ANG II and AVP the same ' proportion of receptor occupancy 1s required for maximal effect (15). This difference appears specific to aortic smooth muscle cells because rat mesenteric arteries, as shown by Hassid and Williams (10) and confirmed in our laboratory (unpublished . observations), exhibit the converse sensitivity to these vasoconstrictor hormones. are in keeping with the notion that AVP receptors in the vascular cells are of the V, subtype. Yet the finding that dDAVP, a pure V2 receptor agonist completely inhibited the AVPinduced prostacyclin synthesis points to a dual involvement of V1 and VZ receptors or to a new and as yet undescribed subtype of AVP receptor for this biological response. The observation that dDAVP was nevertheless also able to potentiate somewhat the response to ANG II points to the possibility that an intracellular signal was generated that rendered the cells more reponsive to a subsequent stimulus.
As already shown previously (3), indomethacin suppressed entirely the ANG II-and AVP-induced prostacyclin synthesis. Superfusion with a calcium-deficient medium reduced but did not suppress completely the agonist-induced prostacyclin synthesis. Nifedipine lacked an inhibitory effect on either ANG II-or AVPinduced prostacyclin release. This lack of responsiveness to nifedipine has been also observed in mesenteric smooth muscle cells (3, 10). It has been previously demonstrated that nifedipine was devoid of an effect on the agonist-induced rise of cytosolic free calcium in monolayer cultures of rat aortic smooth muscle cells (1, 20) . The residual modest synthesis of prostacyclin observed when the medium was deficient in calcium is consistent with our previous observation (1) that removal of extracellular calcium had no effect on the early transient rise of cytosolic free calcium induced by ANG II or AVP. In view of the duration of the cells exposure to this markedly calcium-deficient medium, a lowering of intracellular calcium must have resulted, explaining the considerable reduction of the biological response. These results confirm the important role of calcium in general for the biosynthesis of prostacyclin (12, 13, 25) and as a modulator of ANG II-, AVP-(I), and serotonin-induced prostacyclin synthesis (3-5). However, neither extracellular calcium nor its entry through nifedipine-sensitive calcium channels appears to be a requisite for AVP to exert its potentiating effect on ANG II-induced prostacyclin synthesis.
In summary, ANG II and AVP induce the biosynthesis of prostacyclin in cultured rat aortic smooth muscle cells. This biological response is modulated by calcium movement not involving voltage-gated channels. ANG II is more potent than AVP yet the latter is able to markedly potentiate the response to the former. Selective antagonists of ANG II and AVP inhibit the immediate production of prostacyclin. Unexpectedly, inhibitors of AVPinduced prostacyclin production do not prevent the AVP potentiation of the response to ANG II. This potentiation can even be elicited by V1 receptor antagonists alone. These data raise questions concerning the nature of the specific ANG II and AVP receptors on VSMC and on subsequent interactions of their common signal transduction system. 
